CA9 and glioblastoma: Similarly, inhibition of CAIX activity with SLC-0111 potentiates the impact of temozolomide treatment in preclinical models of glioblastoma (Boyd et al., 2017), and combining CAIX inhibition with immune checkpoint blockade enhances anti-tumour efficacy an in vivo model of melanoma (Chafe et al., 2019).